Caroline Seymour | Authors


Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma After RVd Treatment

June 05, 2022

At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.

Six-Year Survival Extends With Brentuximab Vedotin Plus Chemotherapy in Hodgkin Lymphoma

June 04, 2022

Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.